Foremost, this translational research demonstrated that betatrophin levels were significantly increased in patients with NAFLD and in various fatty liver mouse models, implying that betatrophin may be a novel biomarker for NAFLD, similar to fetuin-A34 or selenoprotein P35. Here, ANGPTL8 is linked to metabolic dysfunction-associated steatotic liver disease.